Effect of Prebiotics Versus Low FODMAPs Diet on Intestinal Microbiota and Symptoms

NCT ID: NCT02210572

Last Updated: 2015-11-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-08-31

Study Completion Date

2015-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

It has been shown that patients complaining of gas-related symptoms significantly improve on a diet low in fermentable residues. However, other studies suggest that some non-absorbable, fermentable meal products (prebiotics) that serve as substrate to colonic bacteria, produce beneficial effects to the host, including improvement of abdominal symptoms. The aim of the study is to compare the effects of a diet low in fermentable residues versus a diet suplemented with prebiotics on intestinal microbiota composition, microbiota activity (intestinal gas production) and digestive symptoms.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Functional Gastrointestinal Disorders

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Intestinal microbiota Intestinal gas Dietary intervention Low-FODMAPs diet Prebiotics

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Bimuno Galacto-oligosaccharide

Dietary intervention

Group Type EXPERIMENTAL

Bimuno Galacto-oligosaccharide 1.37 g/d

Intervention Type DIETARY_SUPPLEMENT

Prebiotic versus low-FODMAPs diet

Low- FODMAPs diet

Dietary intervention

Group Type PLACEBO_COMPARATOR

Low- FODMAPs diet

Intervention Type DIETARY_SUPPLEMENT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bimuno Galacto-oligosaccharide 1.37 g/d

Prebiotic versus low-FODMAPs diet

Intervention Type DIETARY_SUPPLEMENT

Low- FODMAPs diet

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Functional digestive disorder with flatulence
* Women and men between the ages of 18 and 80 years (bounds included at the inclusion visit).
* Normal body weight or with overweight (body mass index between 18.0 and 30.0 kg/m2 (bounds included)).
* Women of childbearing potential should be using or complying with one of the medically approved methods of contraception such as, but not exclusively, one of the following:

1. Birth control pill
2. Intra-uterine device (IUD)
3. Double barrier methods (such as condoms and spermicide)
4. Abstinence
* Willing to follow strict dietary instructions for the duration of the study
* Able to communicate well with the investigator and to comply with the requirements for the study.

Exclusion Criteria

* Significant illness other than functional bowel disorders
* Disease/disorders which can interfere with the collection of the gas (hemorrhoids,..etc)
* Antecedents of digestive surgery, excluding appendicectomy
* Intake of antibiotics in the month (within 30 days) preceding the inclusion visit.
* Current use of any medications with potential central nervous system effects as judged by the investigator (including but not limited to antidepressants, anxiolytics, opiate pain medications)
* Taking drugs that might modify gastrointestinal function
* Change of dietary habits within the preceding 4 weeks (for instance start of a diet high in fiber) or planned change (For example to start a diet) during the period of the study
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hospital Universitari Vall d'Hebron Research Institute

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Fernando Azpiroz, MD

Role: PRINCIPAL_INVESTIGATOR

Vall d'Hebron Research Institute

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Vall d'Hebron Research Institute

Barcelona, Barcelona, Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Spain

References

Explore related publications, articles, or registry entries linked to this study.

Huaman JW, Mego M, Manichanh C, Canellas N, Canueto D, Segurola H, Jansana M, Malagelada C, Accarino A, Vulevic J, Tzortzis G, Gibson G, Saperas E, Guarner F, Azpiroz F. Effects of Prebiotics vs a Diet Low in FODMAPs in Patients With Functional Gut Disorders. Gastroenterology. 2018 Oct;155(4):1004-1007. doi: 10.1053/j.gastro.2018.06.045. Epub 2018 Jun 30.

Reference Type DERIVED
PMID: 29964041 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PR(AG)296/2013/A-4/2014

Identifier Type: -

Identifier Source: org_study_id